Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Pleuropulmonary Fibrosis After Long-term Treatment With the Dopamine Agonist Pergolide for Parkinson Disease
Arch Neurol 62:1290-1295, Tintner,R.,et al, 2005
Pleuropulmonary Disease Associated with Dopamine Agonist Therapy
Ann Neurol 30:613-616, Bhatt,M.H.,et al, 1991
Dystonia-Parkinson Syndrome:Differential Effects of Levodopa and Dopamine Agonists
Clin Neuropharmacol 9:298-302, Klawans,H.L.&Paleologos,N., 1986
Progressive Supranuclear Palsy:Clinical Features & Response to Treatment in 16 Patients
Ann Neurol 13:273-278, Jackson,J.A.,et al, 1983
Treatment of Advanced Parkinson Disease With Pergolide
Neurol 31:675-682, Lieberman,A.,et al, 1981
Long-Term Effectivenss of Dopamine Agonists and Monoamine Oxidase B Inhibitors Compared with Levodopa as Initial Treatment for Parkinsons Disease (PD MED): A Large, Open-Label, Pragmatic Randomised Trial
Lancet 383: Doi: 10.1016/S0140-6736, PD MED Collaborative Group, 2014
Restless Genital Syndrome in Parkinson Disease
JAMA Neurol 71:1559-1561, Aquino, C.C.,et al, 2014
Clinical Features of Dopamine Agonist Withdrawal Syndrome in a Movement Disorders Clinic
JNNP 84:130-135, Pondal, M.,et al, 2013
Extended-Release Pramipexole in Advanced Parkinson Disease
Neurol 77:767-774, Schapira, A.H.V.,et al, 2011
Dopamine Agonist Withdrawal Syndrome in Parkinson Disease
Arch Neurol 67:58-63, Rabinak,C. &Nirenberg,M., 2010
Prolactinomas
NEJM 362:1219-1226, Klibanski,A., 2010
Othello Syndrome in Parkinson Disease Patients Without Dementia
The Neurologist 15:34-36, Cannas,A.,et al, 2009
Long-Term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease
Arch Neurol 66:563-570, Parkinson Sutdy Group CALM Cohort Investigators, 2009
Invited Article: Changing Concepts in Parkinson Disease: Moving Beyond the Decade of the Brain
Neurol 70:1996-2003, Marras,C. &Lang,A., 2008
Fourteen-Year Final Report of the Randomized PDRG-UK Trial Comparing Three Treatments in PD
Neurol 71:474-480.470, Katzenschlager,R.,et al., 2008
Functional Abnormalities Underlying Pathological Gambling in Parkinson Disease
Arch Neurol 65:1604-1611, Cilia,R.,et al, 2008
Levodopa for the Treatment of Parkinsons Disease
NEJM 359:2468-2476, LeWitt,P.A., 2008
Valvular Heart Disease and the Use of Dopamine Agonists for Parkinsons Disease
NEJM 356:39-46, Zanettini,R.,et al, 2007
Dopamine Agonists and the Risk of Cardiac Valve Regurgitation
NEJM 356:29-38, Schade,R.,et al, 2007
Randomized, Blind, Controlled Trial of Transdermal Rotigotine in Early Parkinson Disease
Neurol 68:272-276, Watts,R.L.,et al, 2007
Cardiac Valve Regurgitation With Pergolide Compared With Nonergot Agonsits in Parkinson Disease
Arch Neurol 64:377-380, Dewey,R.B.,Jr, et al, 2007
Advanced Parkinson Disease Treated with Rotigotine Transdermal System PREFER Study
Neurol 68:1262-1267, LeWitt,P.A.,et al, 2007
Transdermal Rotigotine: Double-Blind, Placebo-Controlled Trial in Parkinson Disease
Arch Neurol 64:676-682, Jankovic,J.,et al, 2007
Risk Factors for the Development of Pedal Edema in Patients Using Pramipexole
Arch Neurol 64:820-824, Kleiner-Fisman,G. &Fisman,D.N., 2007
Treatment Options in the Modern Management of Parkinson Disease
Arch Neurol 64:1083-1088, Schapira,A.H.V., 2007
Ropinirole 24-Hour Prolonged Release: Randomized, Controlled Study in Advanced Parkinson Disease
Neurol 68:1108-1115, Pahwa,R.,et al, 2007
Hiccups Associated with Dopamine Agonists in Parkinson Disease
Neurol 66:774-775, Sharma,P.,et al, 2006
Prospective Prevalence of Pathologic Gambling and Medication Association in Parkinson Disease
Neurol 66:1750-1752, Voon,V.,et al, 2006
Dopamine Agonists and Cardiac Valvulopathy in Parkinson Disease: A Case-Control Study
Neurol 67:1225-1229, Yamamoto,M.,et al, 2006
Acromegaly
NEJM 355:2558-2573, Melmed,S., 2006
Sudden Uncontrollable Somnolence and Medication Use in Parkinson Disease
Arch Neurol 62:1242-1248, Avorn,J.,et al, 2005
Diagnosis and Initial Management of Parkinsons Disease
NEJM 353:1021-1027, Nutt,J.G.&Wooten,G.F., 2005
Pathological Gambling Caused by Drugs Used to Treat Parkinson Disease
Arch Neurol 62:1377-1381, Dodd,M.L.,et al, 2005
Cabergoline-Related Severe Restrictive Mitral Regurgitation
NEJM 353:1974-1975, Rosen,C.J., 2005
Treatment of Parkinson's Disease with Pergolide and Relation to Restrictive Valvular Heart Disease
Lancet 363:1179-1183, Van Camp,G.,et al, 2004
Slowing Parkinson's Disease Progression
Neurol 60:381-389, Ahlskog,J.E., 2003
Initial Agonist Treatment of Parkinson Disease
Neurol 60:390-394, Albin,R.L. &Frey,K.A., 2003
[123I]b-CIT SPECT is a Useful Method for Monitoring Dopaminergic Degeneration in Early Stage Parkinson's Disease
JNNP 74:294-298,287, Winogrodzka,A.,et al, 2003
Pathological Gambling Associated with Dopamine Agonist Therapy in Parkinson's
Neurol 61:422-423, Driver-Dunckley,E.,et al, 2003
Heart Valvular Disease in Patients with Parkinson's Disease Treated with High-Dose Pergolide
Neurol 61:859-861, VanCamp,G.,et al, 2003
Prolactinoma
NEJM 349:2035-2041, Schlechte,J.A., 2003
A Controlled Trial of Rotigotine Monotherapy in Early Parkinson's Disease
Arch Neurol 60:1721-1728, The Parkinson Study Group, 2003
Excessive Daytime Sleepiness and Sudden-Onset Sleep in Parkinson Disease
JAMA 287:455-463,509, Hobson,D.E.,et al, 2002
Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs Levodopa on Parkinson Disease Progression
JAMA 287:1653-1661, Parkinson Study Group, 2002
A randomized,Double-blind,Placebo-Controlled Trial of Subcutaneously Injected Apomorphine for Parkinsonian Off-State Events
Arch Neurol 58:1385-1392, Dewey,R.B.,et al, 2001
Ten-year Follow-up of Three Different Initial Treatments in De-novo PD
Neurol 57:1687-1694, Lees,A.J.,et al, 2001
Dopamine Agonists: Their Role in the Treatment of Parkinson's Disease
JNNP 68;685-690, Brooks,D.J., 2000